Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022

13 Aug 2019

• By Sten Stovall

The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.

Add_To_Cart — CDZ173 is in late-stage trials for treating APDS • Source: Shutterstock

The Dutch rare disease company Pharming Group NV has embarked on expansion by acquiring an exclusive global license to CDZ173 (leniolisib), a late-stage small-molecule drug for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immune deficiency, in return for an upfront payment of $20m to Novartis AG as well as potential milestone and royalty payments.

CDZ173 is currently in a pivotal Phase II/III clinical trial as a treatment for APDS. Novartis has completed all the...